デスモイド腫瘍の世界市場レポート 2024

デスモイド腫瘍の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.7%の年間複合成長率（CAGR）で38億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、標的療法の開発、個別化医療の実施、国際協力の増加、新しい治療法の規制当局の承認、患者中心のアプローチの採用などの要因に起因すると考えられます。予測期間中に予想される注目すべき動向には、治療アプローチの進歩、精密医療とバイオマーカー発見の進歩、臨床試験と調査における取り組み、学際的な治療チームの活用、患者擁護とサポートの重視などが含まれます。

がん症例の予想される増加は、将来のデスモイド腫瘍市場の成長を促進する態勢が整っています。異常な細胞の増殖と転移を特徴とするがんは、世界的に健康上の重大な課題を引き起こしています。世界中でがん症例数が増加していることにより、先進的で効果的な化学療法剤の需要が高まり、デスモイド腫瘍市場にプラスの影響を与えています。たとえば、American Cancer Society Inc.のデータによると、2020年に米国では新たに180万人のがん患者が発生し、がん関連の死亡者数は606,520人でした。 2021年の予測では、新たながん患者数は190万人、死亡者数は60万8,570人に増加することが示されています。したがって、がんの有病率の上昇は、デスモイド腫瘍市場の成長を促進する重要な要因です。

研究開発に対する政府の資金配分の増加により、デスモイド腫瘍市場が拡大すると予想されます。政府の資金提供は、科学研究、医療インフラ、治療へのアクセスの改善に対する財政的支援を提供することにより、腫瘍の調査と治療を進める上で極めて重要な役割を果たしています。これにより、最終的にがんの予防、診断、患者の転帰が向上します。その一例は、がんムーンショットのために米国議会によって2023会計年度に国立がん研究所に割り当てられた73億米ドルの予算であり、これは2022年から4億800万米ドル増加しています。その結果、研究開発のための政府資金の増加がデスモイド腫瘍市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のデスモイド腫瘍市場、治療別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 手術
• 放射線治療
• 抗炎症薬
• ホルモン療法
• 化学療法
• 新たな分子標的療法
• その他の治療
• 世界のデスモイド腫瘍市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 生検
• 電子顕微鏡検査
• 免疫組織化学的分析
• その他の診断
• 世界のデスモイド腫瘍市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院と診療所
• 専門センター
• その他のエンドユーザー

第7章 地域および国の分析

• 世界のデスモイド腫瘍市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のデスモイド腫瘍市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デスモイド腫瘍市場の競合情勢
• デスモイド腫瘍市場の企業プロファイル
  • Pfizer Inc.
  • F.Hoffmann-La Roche Ltd.
  • Abbvie Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の大手および革新的な企業

• Abbott Laboratories
• Amgen Inc.
• Stryker Corporation
• Genome And Company
• Vertex Pharmaceuticals Incorporated
• Eisai Limited
• Beckman Coulter Inc.
• Incyte Corporation
• Ipsen Biopharmaceuticals Inc.
• BeiGene Ltd.
• Janssen Biotech Inc.
• Ionis Pharmaceuticals Inc.
• Ayala Pharmaceuticals Inc.
• Blueprint Medicines Corporation
• Xencor Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Desmoid tumors are rare non-cancerous (benign) growths originating from connective tissue cells, typically within the fascia- the tissue encompassing muscles, nerves, and blood vessels. Although locally aggressive, meaning they can grow and invade nearby structures, desmoid tumors differ from traditional cancers as they do not metastasize to distant parts of the body.

The primary treatments for desmoid tumors encompass surgical intervention, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapy, and other therapeutic approaches. Surgery involves the removal or repair of tissues or organs within the body. The diagnosis of desmoid tumors employs various methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and others. Medical professionals in hospitals, clinics, specialty centers, and similar healthcare facilities typically undertake these diagnostic and treatment procedures.

The desmoid tumors market research report is one of a series of new reports from The Business Research Company that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The desmoid tumors market size has grown strongly in recent years. It will grow from $2.76 billion in 2023 to $2.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to several factors, including advancements in medical imaging, progress in genetic research and understanding, innovations in surgical techniques, increased awareness and education, and the efforts of patient advocacy.

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period can be attributed to factors such as the development of targeted therapies, the implementation of personalized medicine, increased international collaborations, regulatory approvals for novel therapies, and the adoption of patient-centric approaches. Notable trends expected in the forecast period include advancements in treatment approaches, progress in precision medicine and biomarker discovery, initiatives in clinical trials and research, the utilization of multidisciplinary treatment teams, and the emphasis on patient advocacy and support.

The anticipated increase in cancer cases is poised to drive the growth of the desmoid tumor market in the future. Cancer, characterized by abnormal cell growth and spreading, poses a significant health challenge globally. The escalating number of cancer cases worldwide has spurred the demand for advanced and effective chemotherapeutic agents, positively impacting the desmoid tumor market. For example, data from the American Cancer Society Inc. revealed that in 2020, the US saw 1.8 million new cancer cases and 606,520 cancer-related fatalities. The projections for 2021 indicated an increase to 1.9 million new cancer cases and 608,570 deaths. Therefore, the rising prevalence of cancer is a key factor driving the desmoid tumor market's growth.

The increasing allocation of government funding for research and development is expected to boost the desmoid tumor market. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and improved access to care. This ultimately enhances cancer prevention, diagnosis, and patient outcomes. An example is the budget of $7.3 billion allocated to the National Cancer Institute by the United States Congress in fiscal year 2023 for the Cancer Moonshot, marking a $408 million increase from 2022. Consequently, the escalating government funding for research and development is fostering the growth of the desmoid tumor market.

The high costs associated with desmoid tumor treatment represent a significant challenge to the market's growth during the forecast period. The expenses for treating desmoid tumors are elevated due to the costs of expensive medications and surgeries. These high costs place a financial burden on patients, varying depending on factors such as the case's complexity, tumor size, and location. According to the National Library of Medicine, the treatment cost for patients with desmoid tumors was reported to be $473,697 in February 2023. Therefore, the substantial treatment costs pose an obstacle to the desmoid tumor market's expansion.

Key companies in the desmoid tumors market are focusing on developing innovative drugs, such as nirogacestat, to address the needs of their existing consumers more effectively. Nirogacestat, an oral, small-molecule gamma-secretase inhibitor, has shown promise for treating desmoid tumors by blocking the production of notch proteins, contributing to tumor cell death. In February 2023, SpringWorks Therapeutics Inc. announced the acceptance and priority review of their new drug application (NDA) for nirogacestat by the U.S. Food and Drug Administration (FDA). This development provides patients with a new treatment option that holds the potential to improve outcomes.

In January 2023, the merger of Advaxis Inc. with Ayala Pharmaceuticals Inc., a US-based biotechnology company, aims to create a unified entity focused on developing and commercializing Ayala's lead program, AL102, for desmoid tumor treatment. The merger intends to expedite the development and commercialization of AL102, fostering a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is actively developing AL102, a vaccine candidate designed to address the treatment of desmoid tumors.

Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company , Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation , Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

North America was the largest region in the desmoid tumors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Desmoid Tumors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on desmoid tumors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for desmoid tumors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The desmoid tumors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
• 2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
• 3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
• Companies Mentioned: Pfizer Inc.; F.Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Desmoid Tumors Market Characteristics

3. Desmoid Tumors Market Trends And Strategies

4. Desmoid Tumors Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Desmoid Tumors Market Size and Growth

• 5.1. Global Desmoid Tumors Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Desmoid Tumors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Desmoid Tumors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Desmoid Tumors Market Segmentation

• 6.1. Global Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Surgery
• Radiation Therapy
• Anti-Inflammatory Medication
• Hormone Therapy
• Chemotherapy
• Novel Molecular-Targeted Therapy
• Other Treatments
• 6.2. Global Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biopsy
• Electron Microscopic Examination
• Immunohistochemical Analysis
• Other Diagnosis
• 6.3. Global Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals And Clinics
• Specialty Centers
• Other End-Users

7. Desmoid Tumors Market Regional And Country Analysis

• 7.1. Global Desmoid Tumors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Desmoid Tumors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Desmoid Tumors Market

• 8.1. Asia-Pacific Desmoid Tumors Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Desmoid Tumors Market

• 9.1. China Desmoid Tumors Market Overview
• 9.2. China Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Desmoid Tumors Market

• 10.1. India Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Desmoid Tumors Market

• 11.1. Japan Desmoid Tumors Market Overview
• 11.2. Japan Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Desmoid Tumors Market

• 12.1. Australia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Desmoid Tumors Market

• 13.1. Indonesia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Desmoid Tumors Market

• 14.1. South Korea Desmoid Tumors Market Overview
• 14.2. South Korea Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Desmoid Tumors Market

• 15.1. Western Europe Desmoid Tumors Market Overview
• 15.2. Western Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Desmoid Tumors Market

• 16.1. UK Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Desmoid Tumors Market

• 17.1. Germany Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Desmoid Tumors Market

• 18.5. France Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Desmoid Tumors Market

• 19.9. Italy Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Desmoid Tumors Market

• 20.13. Spain Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Desmoid Tumors Market

• 21.1. Eastern Europe Desmoid Tumors Market Overview
• 21.2. Eastern Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Desmoid Tumors Market

• 22.1. Russia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Desmoid Tumors Market

• 23.1. North America Desmoid Tumors Market Overview
• 23.2. North America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Desmoid Tumors Market

• 24.1. USA Desmoid Tumors Market Overview
• 24.2. USA Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Desmoid Tumors Market

• 25.1. Canada Desmoid Tumors Market Overview
• 25.2. Canada Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Desmoid Tumors Market

• 26.1. South America Desmoid Tumors Market Overview
• 26.2. South America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Desmoid Tumors Market

• 27.1. Brazil Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Desmoid Tumors Market

• 28.1. Middle East Desmoid Tumors Market Overview
• 28.2. Middle East Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Desmoid Tumors Market

• 29.1. Africa Desmoid Tumors Market Overview
• 29.2. Africa Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Desmoid Tumors Market Competitive Landscape And Company Profiles

• 30.1. Desmoid Tumors Market Competitive Landscape
• 30.2. Desmoid Tumors Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F.Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Abbvie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Desmoid Tumors Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Amgen Inc.
• 31.3. Stryker Corporation
• 31.4. Genome And Company
• 31.5. Vertex Pharmaceuticals Incorporated
• 31.6. Eisai Limited
• 31.7. Beckman Coulter Inc.
• 31.8. Incyte Corporation
• 31.9. Ipsen Biopharmaceuticals Inc.
• 31.10. BeiGene Ltd.
• 31.11. Janssen Biotech Inc.
• 31.12. Ionis Pharmaceuticals Inc.
• 31.13. Ayala Pharmaceuticals Inc.
• 31.14. Blueprint Medicines Corporation
• 31.15. Xencor Inc.

32. Global Desmoid Tumors Market Competitive Benchmarking

33. Global Desmoid Tumors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Desmoid Tumors Market

35. Desmoid Tumors Market Future Outlook and Potential Analysis

• 35.1 Desmoid Tumors Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Desmoid Tumors Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Desmoid Tumors Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer